PDF herunterladen
Open Access
CC BY 4.0 · Brazilian Journal of Oncology 2018; 14(50): 1-5
DOI: 10.5935/1806-6054.20190008
Review Articles

2018 in review: gynecologic cancer insights

2018 em revisão: insights sobre câncer ginecológico

Autoren

  • Eduardo Paulino

    1   Grupo Brasileiro de Tumores Ginecológicos, Grupo EVA - Belo Horizonte - MG - Brazil
    2   Instituto Nacional de Câncer, Medical Oncology - Rio de Janeiro - RJ - Brazil
    3   Grupo Oncoclínicas, Medical Oncology - Rio de Janeiro - RJ - Brazil

  • Aknar F.C. Calabrich

    1   Grupo Brasileiro de Tumores Ginecológicos, Grupo EVA - Belo Horizonte - MG - Brazil
    4   Clínica AMO, Medical Oncology - Salvador - BA - Brazil

  • Andrea P.G. Guimarães

    1   Grupo Brasileiro de Tumores Ginecológicos, Grupo EVA - Belo Horizonte - MG - Brazil
    8   AC Camargo Cancer Center, Medical Oncology - São Paulo - SP - Brazil

  • Andreia C. Melo

    1   Grupo Brasileiro de Tumores Ginecológicos, Grupo EVA - Belo Horizonte - MG - Brazil
    2   Instituto Nacional de Câncer, Medical Oncology - Rio de Janeiro - RJ - Brazil
    3   Grupo Oncoclínicas, Medical Oncology - Rio de Janeiro - RJ - Brazil

  • Daniela Freitas

    1   Grupo Brasileiro de Tumores Ginecológicos, Grupo EVA - Belo Horizonte - MG - Brazil
    6   Instituto do Câncer do Estado de São Paulo, Medical Oncology - São Paulo - SP - Brazil
    7   Hospital Sírio Libanês, Medical Oncology - São Paulo - SP - Brazil

  • Fernando C. Maluf

    1   Grupo Brasileiro de Tumores Ginecológicos, Grupo EVA - Belo Horizonte - MG - Brazil
    9   Beneficência Portuguesa, Medical Oncology - São Paulo - SP - Brazil
    10   Hospital Albert Einstein, Medical Oncology - São Paulo - SP - Brazil

  • Lilian D. Faroni

    1   Grupo Brasileiro de Tumores Ginecológicos, Grupo EVA - Belo Horizonte - MG - Brazil
    5   Américas Centro de Oncologia Integrado, Radiation Oncology - Rio de Janeiro - RJ - Brazil

  • Marcelo A. Vieira

    1   Grupo Brasileiro de Tumores Ginecológicos, Grupo EVA - Belo Horizonte - MG - Brazil
    12   Barretos Cancer Hospital, Gynecologic Oncology - Barretos - SP - Brazil

  • Reitan Ribeiro

    1   Grupo Brasileiro de Tumores Ginecológicos, Grupo EVA - Belo Horizonte - MG - Brazil
    11   Hospital Erasto Gartner, Gynecologic Oncology - Curitiba - PR - Brazil

  • Angelica Nogueira-Rodrigues

    1   Grupo Brasileiro de Tumores Ginecológicos, Grupo EVA - Belo Horizonte - MG - Brazil
    13   DOM Oncologia, Medical Oncology - Divinópolis - MG - Brazil
    14   Universidade Federal de Minas Gerais, Medical Oncology - Belo Horizonte - MG - Brazil

Financial support: none to declare.
Weitere Informationen
  Lizenzen und Reprints Alle Artikel dieser Rubrik

ABSTRACT

Gynecologic cancers constitute an important burden of disease around the world. Estimates from GLOBOCAN 2018 reveals approximately 1,247,300 incident casesand 596,000 related deaths of cancers of the uterine cervix, corpus uteri, and ovarian, annually around the world. In 2018 lots of promising results to improve disease control have been presented at international gynecological cancer meetings. The current review highlights some of the top gynecologic cancer news of 2018, including the new standard of care for BRCAmutant ovarian cancer patients with maintenance olaparib in first line, benefit of bevacizumab rechallenge for relapsed ovarian cancer patients, and the unexpected results of worse overall survival with minimally invasive surgery in early cervical cancer, among others.

RESUMO

Os tumores ginecológicos constituem um verdadeiro fardo à saúde feminina mundialmente. Estimativas do GLOBOCAN 2018 demonstram cerca de 1.247.300 casos e 596.000 mortes anualmente relacionadas aos tumores ginecológicos. Em 2018 foram apresentados trabalhos importantes sobre o manejo destes tumores nos principais congressos internacionais. Esse artigo de revisão destaca alguns destes trabalhos como a manutenção de olaparibe em primeira linha para as pacientes com câncer de ovário e mutação de BRCA, o benefício da re-exposição ao bevacizumabe para pacientes com câncer de ovário recidivado (platino sensível), os resultados inesperados da cirurgia minimamente invasiva em câncer de colo uterino inicial, dentre outros.

Keywords:

Gynecologic cancer - review - 2018

Descritores:

Neoplasias Genitais Femininas - Revisão


Publikationsverlauf

Eingereicht: 25. Dezember 2018

Angenommen: 26. Dezember 2018

Artikel online veröffentlicht:
07. März 2025

© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • REFERENCES

  • Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R. et al Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med 2018; 379 (20) 1895-1904
    CrossrefPubMedSuche in Google Scholar
  • Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa S. et al Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol 2018; 36 (15 Suppl): 5506
    Suche in Google Scholar
  • Pfisterer J, Dean AP, Baumann K, Rau J, Harter P, Joly F. et al Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG). Ann Oncol 2018; 29 (Suppl 8): viii332-viii358
    CrossrefSuche in Google Scholar
  • Du Bois A, Vergote I, Ferron G, Reuss A, Meier W, Greggi S. et al Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 2017; 35 (15 Suppl): 5501
    Suche in Google Scholar
  • Coleman RL, Enserro D, Spirtos N, Herzog TJ, Sabbatini P, Armstrong DK. et al A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. J Clin Oncol 2018; 36 (15 Suppl): 5501
    CrossrefSuche in Google Scholar
  • Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL. et al Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18 (06) 77991
    CrossrefPubMedSuche in Google Scholar
  • Wortman BG, Creutzberg CL, Putter H, JürgenliemkSchulz IM, Jobsen JJ, Lutgens LCHW. et al PORTEC Study Group. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 2018; 119 (09) 1067-1074
    CrossrefPubMedSuche in Google Scholar